Shares of BioMarin Pharmaceutical BMRN were up 3% in pre-market trading today after the company reported positive top-line ...

BioMarin Pharmaceutical, a San Rafael biotech company known for treating extremely rare diseases, said Wednesday it’s laying off 225 workers, most of whom live and work in California. The cuts come ...

Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring ...

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company ...

The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo ...

View BioMarin Pharmaceutical Inc. BMRN stock quote prices, financial information, real-time forecasts, and company news from CNN.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the stocks that could 10x by 2030. On May 22, H.C. Wainwright reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $50 ...

By Sneha S K and Kunal Das May 18 (Reuters) - BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study. The ...

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California ...

After quite the regulatory process, with Roctavian (valoctocogene roxaparvovec) BioMarin has a potential blockbuster. On June 29th, Roctavian became the first gene therapy approved in the U.S. in the ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the stocks that could 10x by 2030. On May 22, H.C. Wainwright reiterated a Neutral rating on BioMarin Pharmaceutical Inc.